LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Axsome Therapeutics Inc

Gesloten

SectorGezondheidszorg

121.87 0.6

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

120.88

Max

123.45

Belangrijke statistieken

By Trading Economics

Inkomsten

11M

-48M

Verkoop

29M

150M

Winstmarge

-31.973

Werknemers

846

EBITDA

20M

-37M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+40.08% upside

Dividenden

By Dow Jones

Volgende Winsten

11 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

497M

5.8B

Vorige openingsprijs

121.27

Vorige sluitingsprijs

121.87

Nieuwssentiment

By Acuity

33%

67%

82 / 372 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Axsome Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 aug 2025, 22:51 UTC

Winsten

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H Rev $4.01B

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H Adj EPS $1.84

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H EPS $1.82

27 aug 2025, 23:50 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 aug 2025, 23:39 UTC

Winsten

Correction to Nvidia Earnings Article -- WSJ

27 aug 2025, 22:59 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 aug 2025, 22:59 UTC

Marktinformatie

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 aug 2025, 22:58 UTC

Winsten

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 aug 2025, 22:57 UTC

Winsten

South32 FY Free Cash Flow $192 Million

27 aug 2025, 22:56 UTC

Winsten

South32 FY Total Capital Expenditure $1.35 Billion

27 aug 2025, 22:56 UTC

Winsten

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 aug 2025, 22:55 UTC

Winsten

South32 Net Cash $123 Million at June 30

27 aug 2025, 22:54 UTC

Winsten

South32: Focused on Maintaining Strong Operating Momentum

27 aug 2025, 22:53 UTC

Winsten

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 aug 2025, 22:53 UTC

Winsten

South32 Extends Capital Management Program for 12 Months

27 aug 2025, 22:52 UTC

Winsten

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 aug 2025, 22:51 UTC

Winsten

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 aug 2025, 22:51 UTC

Winsten

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 aug 2025, 22:50 UTC

Winsten

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 aug 2025, 22:50 UTC

Winsten

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 aug 2025, 22:45 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 aug 2025, 22:44 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 aug 2025, 22:44 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 aug 2025, 22:43 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 aug 2025, 22:43 UTC

Winsten

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 aug 2025, 22:42 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 aug 2025, 22:42 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 aug 2025, 22:40 UTC

Winsten

Sandfire Resources Net Debt $123 Million at June 30

27 aug 2025, 22:40 UTC

Winsten

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer Vergelijking

Prijswijziging

Axsome Therapeutics Inc Prognose

Koersdoel

By TipRanks

40.08% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 169.71 USD  40.08%

Hoogste 200 USD

Laagste 144 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Axsome Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

16

Buy

0

Hold

0

Sell

Technische score

By Trading Central

107.24 / 112.29Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

82 / 372 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.